For instance, in ALK-positive non-small cell lung cancer (NSCLC), treatment with alectinib induces a DTP state characterized by activation of YAP–TEAD and Wnt/β-catenin pathway signaling, contributing to persistence and eventual relapse in patient-derived NSCLC models (Fujimura et al., 2024). The gene discussed is ALK; the disease is non-small cell lung carcinoma.